Tanja Obradovic
May 16, 2025, 02:19
Tanja Obradovic Highlights KEYNOTE-B96 Phase 3 Success in Ovarian Cancer
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, posted on LinkedIn:
“Outstanding achievement today of Merck’s Woman’s Cancer Development team lead by outstanding expert in the field Gursel Aktan who continues to lead toward historic movements in cancer immunotherapy opening new frontiers for gynecological cancer patients.
Just announced that Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65) met its primary endpoint of progression-free survival (PFS) as well as secondary endpoint of overall survival (OS) in for the treatment of patients with platinum-resistant recurrent ovarian cancer whose tumors expressed PD-L1.
The study was also positive for all-comers PFS while all-comers OS is pending. Keytruda (pembrolizumab), was tested in combination with chemotherapy (paclitaxel) with or without bevacizumab.
Amazing news for ovarian cancer patients with platinum-resistant PDL-1 positive disease who have a large medical need as KEYNOTE-B96 delivers for the first time an immune checkpoint inhibitor-based regimen that delivers an overall survival benefit in this population. It also opens hope for PDL-1 negative patients as PFS was positive in all-comers and total population OS results may come soon.”
More posts featuring Tanja Obradovic on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 16, 2025, 02:19
May 16, 2025, 02:14
May 16, 2025, 00:23
May 15, 2025, 18:17
May 15, 2025, 17:41